Dr Esterre's question

desjeuxp at who.ch desjeuxp at who.ch
Wed Oct 28 10:26:33 BRST 1998


There was a paper published in Transactions,1996, 90, 187-188 "Failure of a
combination of two antifungal drugs, terbinafine plus itrakonazole in Sudanese
post kala azar dermal leishmaniasis by Khalil, E.A.G. et al.

Regards.

P. Desjeux, CTD/TRY 

____________________Reply Separator____________________
Subject:    Dr Esterre's question
Author: Jeffrey Shaw <jshaw at tba.com.br>
Date:       26-Oct-1998 15:52

>Date: Sun, 25 Oct 1998 09:42:09 +0100
>Date: Thu, 22 Oct 1998 09:37:20
>To: tdr-scientists at who.ch
>From: Philippe Esterre <esterre at malarde.pf>
>Subject: Terbinafine in CL ?
>
>What about terbinafine in the treatment of Cutaneous Leishmaniasis ?
>*******************************************************************
>
>        Thanks for the WHO/TDR secretary staff for sending an up-dated
>information
>on the so-called ADVANCES IN BATTLE AGAINST LEISHMANIASIS (message
>22.10.1998, from WHO/TDR Newsletter 57). Vaccine with or without BCG and,
>perhaps more realistic, injectable aminosidine seem to have the potential
>to become future weapons against leishmaniasis but with some delay..
>
>        But what about the new allylamine drug, terbinafine (a very potent
>antifungic drug from Novartis laboratories) ? It seems that some limited
>scale trials with terbinafine have been organized at least against
>Cutaneous Leishmaniasis ? 
>Is there somebody in the TDR-scientists community who can make an
>assessment of what is presently known on this new family of molecules ..
>
>Best regards for all - Philippe Esterre
>International Network of Pasteur Institutes
>------------------------------------------
>
>Dr. Philippe ESTERRE - Head of Immunology Unit 
>Institut de Recherches Medicales L. Malarde
>BP30  98713-Papeete (TAHITI)- French Polynesia
>Phone: 689 41 64 67 - Fax: 689 43 15 90
>Mail: esterre at malarde.pf
>
>


More information about the Leish-l mailing list